AI-Designed Phages Given to a Patient in Experimental Treatment
A patient with an antibiotic-resistant bacterial infection has received a treatment containing bacteriophages designed with help from artificial intelligence, according to biotechnology company Radical Numerics. The company says the treatment was given under a physician-led compassionate-use pathway.
Bacteriophages, or phages, are viruses that infect bacteria. They are distinct from viruses that infect human cells. In this case, the company says its Omnii-1 model helped design phages for a specific bacterial target.
What did the AI help design?
Radical Numerics says it used Omnii-1 to design phage variants and tested a treatment cocktail against the patient’s bacterial sample in the laboratory. The company reports that the cocktail eliminated the sample in vitro before it was administered.
ProPakistani and reporting by The New York Times identify the infection as antibiotic-resistant E. coli. The company has not shared the patient’s clinical course or outcome, citing privacy. It is not known from the public information whether the infection improved after treatment.
What does compassionate use mean?
The treatment was not described as an approved therapy for general use. The company says it was administered to one patient through a physician-led compassionate-use pathway. ProPakistani, citing The New York Times, reports that the US Food and Drug Administration authorized the treatment.
Compassionate use, also called expanded access in the United States, can allow a patient with a serious condition to receive an investigational medical product outside a clinical trial when satisfactory alternatives are unavailable. It is a pathway for access, not evidence that a treatment is proven effective or approved for wider use.
Is this the first use of phage therapy?
No. Phage therapy has been used in some settings for many years. The “first” claim here refers more narrowly to the company’s report of AI-designed phages being administered to a human patient.
Earlier research published in Science showed that AI-designed bacteriophages could be produced and tested in laboratory conditions. That work was separate from this patient treatment and did not establish that AI-designed phages work as a therapy in people.
What is known about the result?
The company has not disclosed the patient’s clinical outcome. Its report says the treatment cocktail worked against the bacterial isolate in laboratory testing, but that result is not the same as proving it cleared an infection in a person.
A single compassionate-use case cannot establish general safety or effectiveness. Broader use would require further clinical evidence and careful evaluation.
Frequently asked questions
What are bacteriophages?
Bacteriophages are viruses that target bacteria. Phage treatments are selected or designed to match the bacteria causing a particular infection.
Did AI cure the patient?
There is no public evidence confirming a cure. The company has not disclosed the patient’s clinical outcome.
Is AI-designed phage treatment available to everyone?
No. The reported case involved an investigational treatment given to one patient under compassionate use. It is not an approved treatment for general use.
Was this the first-ever phage treatment in a person?
No. The reported milestone is the company’s claim that AI-designed phages were used in a human patient for the first time. Phage therapy itself predates this case.